OCRX
Ocera Therapeutics, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Feb. 8, 2013, 8:36 AM

    Drugmaker Tranzyme (TZYM) +11.7% premarket on news it will explore a possible sale of the company, less than two years after it went public. Two mid-stage trials of its development drug for stomach paralysis recently were dropped due to lack of efficacy.

    | Feb. 8, 2013, 8:36 AM